Biologic agents have revolutionized the management of some inflammatory diseases like rheumatoid arthritis,\r\nseronegative spondyloarthropathies and Crohn�s disease; the selective inhibition of mediators involved in systemic\r\nchronic processes have allowed to expand the knowledge among the complex pathogenic pathways that are involved\r\nin inflammation and damage.\r\nThe off-label use of biologic drugs is expanding. This review highlights the theoretical basis that may support\r\nthe use of biologic drugs in the treatment of Systemic Sclerosis (SSc), a disabling and sometimes devastating\r\ndisease whose treatment remains largely unsatisfactory. Some progresses have been made concerning the vascular\r\ncomplications of the disease, but the skin and visceral fibrosis, which is the hallmark of the disease, is still orphan of\r\neffective therapy. Moreover the results of the limited clinical experience about biologic agent administration in SSc and\r\nSSc-interstitial lung disease are presented.
Loading....